SYVC Synovics Pharmaceuticals, Inc., featured news, full reports, and detailed SYVC.OB charts.
Synovics Pharmaceuticals, Inc. (SYVC/SYVC.OB) Wrap Up:
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products. The companyâs OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It also offers private label solid dosage Rx products, including Estratest, a product used by post-menopausal women. Synovics Pharmaceuticals packages and distributes its private label, or store brand OTC products to chain drug stores, wholesalers, and distributors in the United States. It has a strategic partnership with Maneesh Pharmaceuticals Pvt., Ltd. The co...
Synovics Pharmaceuticals, Inc. (SYVC:OTC Bulletin Board Market)
Snapshot of Synovics Pharmaceuticals, Inc. (SYVC)
|
OPEN
--
|
PREVIOUS CLOSE
$0.07
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
11/13/08 - $0.37
|
52 WEEK LOW
08/12/09 - $0.03
|
|
|
MARKET CAP
1.9M
|
AVERAGE VOLUME 3 mo
1.4K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
29.8M
|
|
|
SYVC Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
SYVC Details
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The companys OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It also offers private label solid dosage Rx products, including Estratest, a product used by post-menopausal women. The company packages and distributes its private label, or store brand OTC products to chain drug stores, wholesalers, and distributors in the United States. It primarily has strategic alliance agreement with Maneesh Pharmaceuticals Pvt., Ltd. and Harcharan (Harry) Singh. The company was formerly known as Bionutrics, Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Ft. Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
SYVC Top Compensated Officers
Executives, Board Directors
Key developments for Synovics Pharmaceuticals, Inc. (SYVC)
Synovics Pharmaceuticals Inc. announced earnings results for the second quarter ended July 31, 2009. Net loss for the quarter was $2.02 million, up/down from $489,670 net loss for the same quarter the previous year (2007-2008).
On 09/15/2009, Synovics Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Synovics Pharmaceuticals Inc. reported earnings results for the second quarter ended April 30, 2009. For the second quarter, the company reported net loss of $2.6 million. In contrast, the company posted a net income of $2.94 million for the same quarter in the previous year.
SYVC Competitors
| Company | Last | Change |
| Advance Plant Pharmaceuticals | $0.0007 USD | 0.00 |
| Bactolac Pharmaceutical Inc | $25,000 USD | 0.00 |
| Eugene Science Inc | $0.0034 USD | 0.00 |
| Kellogg Co | $52.20 USD | -0.03 |
| Perrigo Co | $39.18 USD | +0.44 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | SYVC | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.1x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
SYVC |
||
SYVC transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Synovics Pharmaceuticals, Inc.
-
Synovics Pharmaceuticals Announces the Settlement of all Legal Proceedings with Nostrum Pharmaceuticals, Inc., Dr. Nirmal Mulye and Anil Anand
PHOENIX -- Synovics Pharmaceuticals, Inc. (OTCBB:SYVC), a specialty pharmaceutical company, today announced that on July 31, 2007, the Company...
Business Wire, 08/06/07 · More from publication